

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Wesolowski John M</u> <hr/> (Last) (First) (Middle) C/O INTENSITY THERAPEUTICS, INC. 61 WILTON ROAD, 3RD FLOOR <hr/> (Street) WESTPORT CT 06880 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/29/2023	3. Issuer Name and Ticker or Trading Symbol <u>INTENSITY THERAPEUTICS, INC. [INTS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) _____ <p style="text-align: center;">Interim CFO</p>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, \$0.0001 Par Value	5,000	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (right to buy Common Stock)	(1)	03/27/2027	Common Stock	15,000	4	D
Stock Option (right to buy Common Stock)	(1)	02/06/2028	Common Stock	7,500	8	D
Stock Option (right to buy Common Stock)	(2)	07/11/2029	Common Stock	2,500	9	D
Stock Option (right to buy Common Stock)	(3)	07/31/2030	Common Stock	6,250	11.5	D
Stock Option (right to buy Common Stock)	(4)	08/13/2031	Common Stock	6,000	11.5	D
Stock Option (right to buy Common Stock)	(5)	09/05/2031	Common Stock	6,500	11.5	D
Stock Option (right to buy Common Stock)	(6)	12/13/2032	Common Stock	12,500	9	D

Explanation of Responses:

- This option is fully vested and exercisable.
- This option is vested and exercisable with regard to 1,875 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., on July 11, 2023.
- This option is vested and exercisable with regard to 3,125 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., in two equal annual installments, beginning on July 31, 2023.
- This option is vested and exercisable with regard to 1,500 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., in three equal annual installments, beginning on August 13, 2023.
- This option is vested and exercisable with regard to 1,625 shares of Common Stock. This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., in three equal annual installments, beginning on September 5, 2023.
- This option will vest with regard to the remaining shares of Common Stock, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four annual installments, beginning on December 13, 2023.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Daniel L. Woodard, Attorney-in-Fact 06/29/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that I, JOHN WESOLOWSKI, hereby constitute and appoint Robert H. Cohen and Daniel L. Woodard, and each of them, my true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for me and in my name, place and stead, to sign any Form ID (Uniform Application for Access Codes to File on EDGAR), reports on Form 3 (Initial Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes in Beneficial Ownership of Securities) and Form 5 (Annual Statement of Beneficial Ownership of Securities) relating to transactions by me in Common Shares or other securities of Intensity Therapeutics, Inc. and all amendments thereto, and to file the same, with the Securities and Exchange Commission and the appropriate securities exchange, granting unto said attorneys-in-fact and agents, and each of them, or their substitutes, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as I might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall be effective until such time as I deliver a written revocation thereof to the above-named attorneys-in-fact and agents.

Dated: December 9, 2021

/s/ John Wesolowski
John Wesolowski